PE20120356A1 - Compuestos para el tratamiento de trastornos metabolicos - Google Patents
Compuestos para el tratamiento de trastornos metabolicosInfo
- Publication number
- PE20120356A1 PE20120356A1 PE2011001633A PE2011001633A PE20120356A1 PE 20120356 A1 PE20120356 A1 PE 20120356A1 PE 2011001633 A PE2011001633 A PE 2011001633A PE 2011001633 A PE2011001633 A PE 2011001633A PE 20120356 A1 PE20120356 A1 PE 20120356A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- oxadiazol
- piperidin
- halo
- acid ester
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE p ES 1 O 2; Z ES N-C(O)OR4, N-C(O)NR4R5, N-CH2-FENILO, ENTRE OTROS; A ES UN GRUPO FENILO O UN ANILLO HETEROARILO DE 6 MIEMBROS QUE CONTIENE UNO O DOS ATOMOS DE NITROGENO; B ES UN ANILLO HETEROARILO DE 5 MIEMBROS QUE CONTIENE UNO O MAS HETEROATOMOS SELECCIONADOS DE N, O Y S O UN ANILLO HETEROARILO DE 6 MIEMBROS QUE CONTIENE UNO O DOS ATOMOS DE NITROGENO; X ES O-CR6H, O, CR6H-O, ENTRE OTROS; R1 ES H, HALO, CIANO, ALQUILO C1-C4, ENTRE OTROS; q ES 1 O 2; R2 ES UN GRUPO (a) O UN GRUPO FENILO OPCIONALMENTE SUSTITUIDO CON HALO O PIRIDILO; R3 ES HALO O METILO; n ES 0 O 1; m ES 0, 1 O 2; R4 ES ALQUILO C2-C6, CICLOALQUILO C3-C6, ENTRE OTROS; R5 ES H O ALQUILO C1-C4; R6 ES H O ALQUILO C1-C2. SON COMPUESTOS PREFERIDOS: ESTER ISOPROPILICO DEL ACIDO 4-[5-(6-CLOROPIRIMIDIN-5-IL)-[1,2,4]OXADIAZOL-3-ILMETOXI]-PIPERIDIN-1-CARBOXILICO, ESTER ISOPROPILICO DEL ACIDO 4-[3-(6-CLORO-PIRIDIN-3-IL)-[1,2,4]OXADIAZOL-5-ILMETOXI]-PIPERIDIN-1-CARBOXILICO, ESTER ISOPROPILICO DEL ACIDO 4-{(R)-1-[5-(2-CLOROPIRIMIDIN-5-IL)-[1,2,4]OXADIAZOL-3-IL]-ETOXI}-PIPERIDIN-1-CARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD COMO AGONISTA DEL RECEPTOR GPR119 Y COMO INHIBIDORES DE LA DPP-IV SIENDO UTILES EN EL TRATAMIENTO DE TRASTORNOS METABOLICOS INCLUYENDO LA DIABETES TIPO II
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0904287.0A GB0904287D0 (en) | 2009-03-12 | 2009-03-12 | Compounds for the treatment of metabolic disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20120356A1 true PE20120356A1 (es) | 2012-04-16 |
Family
ID=40600949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011001633A PE20120356A1 (es) | 2009-03-12 | 2010-03-12 | Compuestos para el tratamiento de trastornos metabolicos |
Country Status (18)
Country | Link |
---|---|
US (1) | US20120040953A1 (es) |
EP (1) | EP2406256A1 (es) |
JP (1) | JP2012520284A (es) |
KR (1) | KR20110130476A (es) |
CN (1) | CN102395584A (es) |
AU (1) | AU2010222673A1 (es) |
BR (1) | BRPI1009781A2 (es) |
CA (1) | CA2754794A1 (es) |
CL (1) | CL2011002221A1 (es) |
EA (1) | EA201190209A1 (es) |
GB (1) | GB0904287D0 (es) |
IL (1) | IL215051A0 (es) |
MA (1) | MA33242B1 (es) |
MX (1) | MX2011009491A (es) |
PE (1) | PE20120356A1 (es) |
SG (1) | SG174362A1 (es) |
WO (1) | WO2010103335A1 (es) |
ZA (1) | ZA201107446B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2445878A1 (en) | 2009-06-24 | 2012-05-02 | Boehringer Ingelheim International GmbH | New compounds, pharmaceutical composition and methods relating thereto |
TW201113269A (en) | 2009-06-24 | 2011-04-16 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
GB201006167D0 (en) * | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB2488360A (en) * | 2011-02-25 | 2012-08-29 | Prosidion Ltd | Heterocyclic GPCR agonists |
AR083904A1 (es) * | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
GB201114389D0 (en) * | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
KR101881932B1 (ko) | 2011-12-07 | 2018-07-27 | 삼성전자주식회사 | 자기 소자 및 그 제조 방법 |
AR091739A1 (es) | 2012-07-11 | 2015-02-25 | Elcelyx Therapeutics Inc | Composiciones y metodos para reducir el riesgo cardiometabolico |
WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
AU2020313312A1 (en) * | 2019-07-15 | 2022-03-03 | Oncoarendi Therapeutics S.A. | Substituted amino triazoles useful as chitinase inhibitors |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
AU756244B2 (en) | 1998-09-01 | 2003-01-09 | Basf Aktiengesellschaft | Methods for improving the function of heterologous G protein-coupled receptors |
US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
AU2004303604B2 (en) * | 2003-12-24 | 2011-03-24 | Prosidion Limited | Heterocyclic derivatives as GPCR receptor agonists |
JP4980928B2 (ja) | 2004-12-24 | 2012-07-18 | プロシディオン・リミテッド | Gタンパク質共役受容体(gpr116)作動薬および肥満および糖尿病治療のためのその使用 |
JP5065908B2 (ja) * | 2004-12-24 | 2012-11-07 | プロシディオン・リミテッド | Gタンパク質結合受容体作動薬 |
GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
WO2007003961A2 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
AU2006264649A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
GB0513257D0 (en) * | 2005-06-30 | 2005-08-03 | Prosidion Ltd | Compounds |
EP1909791A1 (en) | 2005-06-30 | 2008-04-16 | Prosidion Limited | G-protein coupled receptor agonists |
US20090325924A1 (en) | 2005-06-30 | 2009-12-31 | Stuart Edward | GPCR Agonists |
JP2009526032A (ja) | 2006-02-09 | 2009-07-16 | アストラゼネカ アクチボラグ | 化合物 |
CA2646676A1 (en) | 2006-04-06 | 2007-10-18 | Prosidion Limited | Heterocyclic gpcr agonists |
GB0607196D0 (en) | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
GB0610746D0 (en) | 2006-06-01 | 2006-07-12 | Prosidion Ltd | Method of treatment |
WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
JP5330260B2 (ja) | 2006-12-06 | 2013-10-30 | スミスクライン ビーチャム コーポレーション | 二環式化合物ならびに抗糖尿病薬としての使用 |
DK2114925T3 (da) | 2006-12-22 | 2012-05-29 | Ind Res Ltd | Azetidin-analoger af nucleosidase- og phosphorylase-inhibitorer |
WO2008081204A1 (en) | 2007-01-04 | 2008-07-10 | Prosidion Limited | Piperidine gpcr agonists |
AR064736A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr |
WO2008081208A1 (en) | 2007-01-04 | 2008-07-10 | Prosidion Limited | Piperidine gpcr agonists |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
CL2008000018A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
PT2173737E (pt) | 2007-07-17 | 2012-03-19 | Bristol Myers Squibb Co | Método para modular receptor gpr119 acoplado a proteína g e compostos seleccionados |
US20100286112A1 (en) | 2007-09-10 | 2010-11-11 | Oscar Barba | Compounds for the treatment of metabolic disorders |
CN101827958A (zh) | 2007-10-18 | 2010-09-08 | 日矿金属株式会社 | 金属包覆的聚酰亚胺复合体、该复合体的制造方法以及电子电路板的制造方法 |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
CN101621337B (zh) | 2008-06-30 | 2013-08-07 | 华为技术有限公司 | 一种时延调节装置与方法 |
GB0812641D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
KR20110036609A (ko) | 2008-07-10 | 2011-04-07 | 프로시디온 리미티드 | 피페리디닐 gpcr 작용제 |
EP2321308B9 (en) | 2008-07-10 | 2012-08-08 | Prosidion Limited | Piperidine gpcr agonists |
GB0812648D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
-
2009
- 2009-03-12 GB GBGB0904287.0A patent/GB0904287D0/en not_active Ceased
-
2010
- 2010-03-12 CA CA2754794A patent/CA2754794A1/en not_active Abandoned
- 2010-03-12 PE PE2011001633A patent/PE20120356A1/es not_active Application Discontinuation
- 2010-03-12 MX MX2011009491A patent/MX2011009491A/es unknown
- 2010-03-12 KR KR1020117024020A patent/KR20110130476A/ko not_active Application Discontinuation
- 2010-03-12 SG SG2011065794A patent/SG174362A1/en unknown
- 2010-03-12 EP EP10709926A patent/EP2406256A1/en not_active Withdrawn
- 2010-03-12 JP JP2011553534A patent/JP2012520284A/ja active Pending
- 2010-03-12 US US13/255,536 patent/US20120040953A1/en not_active Abandoned
- 2010-03-12 MA MA34246A patent/MA33242B1/fr unknown
- 2010-03-12 AU AU2010222673A patent/AU2010222673A1/en not_active Abandoned
- 2010-03-12 BR BRPI1009781A patent/BRPI1009781A2/pt not_active Application Discontinuation
- 2010-03-12 CN CN2010800164285A patent/CN102395584A/zh active Pending
- 2010-03-12 WO PCT/GB2010/050442 patent/WO2010103335A1/en active Application Filing
- 2010-03-12 EA EA201190209A patent/EA201190209A1/ru unknown
-
2011
- 2011-09-08 CL CL2011002221A patent/CL2011002221A1/es unknown
- 2011-09-08 IL IL215051A patent/IL215051A0/en unknown
- 2011-10-11 ZA ZA2011/07446A patent/ZA201107446B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP2406256A1 (en) | 2012-01-18 |
BRPI1009781A2 (pt) | 2016-03-08 |
IL215051A0 (en) | 2011-11-30 |
MX2011009491A (es) | 2011-10-11 |
CL2011002221A1 (es) | 2012-07-06 |
MA33242B1 (fr) | 2012-05-02 |
JP2012520284A (ja) | 2012-09-06 |
EA201190209A1 (ru) | 2012-04-30 |
SG174362A1 (en) | 2011-11-28 |
AU2010222673A1 (en) | 2011-11-03 |
CN102395584A (zh) | 2012-03-28 |
US20120040953A1 (en) | 2012-02-16 |
ZA201107446B (en) | 2012-06-27 |
KR20110130476A (ko) | 2011-12-05 |
WO2010103335A1 (en) | 2010-09-16 |
GB0904287D0 (en) | 2009-04-22 |
CA2754794A1 (en) | 2010-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20120356A1 (es) | Compuestos para el tratamiento de trastornos metabolicos | |
PE20081836A1 (es) | Derivados de piperidina como inhibidores de la sintasa de acido graso | |
PE20110136A1 (es) | Compuestos organicos | |
PE20060937A1 (es) | Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) | |
PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
PE20191757A1 (es) | Compuestos heterociclicos utiles como inhibidores dobles de atx/ca | |
PE20090773A1 (es) | Derivados de morfolina pirimidina | |
PE20120399A1 (es) | Derivados del l-(piperidin-4-il)-pirazol como moduladores de gpr 119 | |
PE20090992A1 (es) | Derivados de fenil-amino-pirimidina como agentes inhibidores de cinasa | |
PE20110843A1 (es) | Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica | |
PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
PE20121159A1 (es) | DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR | |
PE20140207A1 (es) | Composiciones y metodos para modular el fxr | |
PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
RU2009148320A (ru) | Производные пиперидина/пиперазина | |
PE20090649A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
AR087196A1 (es) | Metodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales ii | |
PE20110063A1 (es) | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK | |
EA201170522A1 (ru) | Новые гетероциклические азотсодержащие соединения, их получение и их применение в качестве антибактериальных лекарственных средств | |
PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
NO20091590L (no) | Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer | |
PE20080275A1 (es) | Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa | |
PE20071177A1 (es) | Derivados de 3,5-piridina como inhibidores de renina | |
PE20120218A1 (es) | Compuestos para el tratamiento de trastornos metabolicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |